Reach Us +32-10-28-02-25
Editor - Thiagarajan Venkatesan | Nova Southeastern University | 26598
ISSN: 2572-5130

Medical Reports & Case Studies
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Thiagarajan Venkatesan

Thiagarajan Venkatesan
Thiagarajan Venkatesan
Associate Research Scientist
Rumbaugh Goodwin Institute for Cancer Research
Nova Southeastern University


Dr. Thiagarajan Venkatesan is currently working as an Associate Research Scientist in Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Florida, USA. He has done his Ph.D in Microbiology-Botany from University of Madras, India. He has also worked as a Research Scientist in R&D in Bharat Biotech and involved in the development of recombinant human vaccine against cancer. His work involved upstream and the downstream processing of cancer related viral antigens to the pilot and large scale levels. Currently he is doing the development of therapeutic proteins against selected targets in cancers. Also he is analyzing the gene expression pattern in highly aggressive cancers. He is an Associate member of the American Association for Cancer Research. He has published research articles in international peer reviewed journals and also presented papers in National and International conferences.

Research Interest

Prognostic and diagnostic markers and novel therapeutic targets for human cancers, development of new therapeutic molecules against cancer, cloning, expression and purification of new biologics, testing the efficacy of small molecules, natural products and therapeutic molecules against various cancers, analyzing the pathway specific gene expression profile.